Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma

IMPORTANCE: Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the Common Terminology Criteria for Adverse Events (C...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Shoushtari, Alexander N., Friedman, Claire F., Navid-Azarbaijani, Pedram, Postow, Michael A., Callahan, Margaret K., Momtaz, Parisa, Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2017
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833656/
https://ncbi.nlm.nih.gov/pubmed/28817755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.2391
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky